HOME > 研究業績詳細


服部 信孝(ハットリ ノブタカ)

研究テーマ 神経学、神経変性疾患、 遺伝性パーキンソン病神経疾患全般
研究業績(論文) 主な英文総説
1 Hattori N, Mizuno Y. Pathogenetic mechanisms of parkin in Parkinson's disease, Lancet, 2004, 364:722- 724, IF: 60.392, CI: 91
2 Kubo S, Hattori N, Mizuno Y. Recessive Parkinson's disease, Mov Disord, 2006, 21:885-893, IF: 8.679, CI:24
3 Kawajiri S, Saiki S, Sato S, Hattori N. Genetic mutations and functions of PINK1, Trends Pharmacol Sci, 2011, 32:573-580, IF: 13.503, CI: 43
4 Shimura H, Mizuno Y, Hattori N. Citation Classic Parkin and Parkinson Disease, Clin. Chem. 2012, 58:1260-1261, IF: 8.008
5 Saiki S, Sato S, Hattori N. Molecular pathogenesis of Parkinson's disease: update, J Neurol Neurosurg Psychiatry, 2012, 83:430-436, IF: 8.234, CI: 51
6 Kubo S, Hattori N. Neurodegenerative disease, Can synucleinopathy and tauopathy be identified during life? ‎Nat. Rev. Neurol 2013, 9:426-427, IF: 21.155
7 Hattori N. Movement disorders: advances in 2015, Lancet Neurol, 2016, 15:8-9, IF: 30.039
8 Lim SY, Tan AH, Ahmad-Annuar A, Klein C, Tan LCS, Rosales RL, Bhidayasiri R, Wu YR, Shang HF, Evans AH, Pal PK, Hattori N, Tan CT, Jeon B, Tan EK, Lang AE. Parkinson's disease in the Western Pacific Region. Lancet Neurol. 2019 Sep;18(9):865-879. IF: 30.039

1 Hattori N, Tanaka M, Ozawa T, Mizuno Y. Immunohistochemical studies on Complex-I Complex-II Complex-III and Complex-IV of mitochondria in Parkinsons-disease, Ann Neurol, 1991, 30:563-571, IF: 9.977, CI: 211
2 Mizuno Y, Matsuda S, Yoshino H, Mori H, Hattori N, Ikebe S. An immunohistochemical study on alpha-Ketoglutarate dehydrogenase complex in Parkinsons-disease, Ann Neurol, 1994, 35:204-210, IF: 9.977, CI: 155
3 Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease, PNAS, 1996, 93:2696-2701, IF: 9.674, CI: 765
4 Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S,. Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature, 1998, 392:605-608, IF: 41.456, CI: 3389
5 Uchida K, Hattori N, Osawa T, et al; Protein-bound acrolein: Potential markers for oxidative stress, PNAS, 1998, 95:4882-4887, IF: 9.674, CI: 473
6 Hattori N, Kitada T, Matsumine H, Mizuno Y, (15人中1番目)et al.; Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the Parkin gene in affected individuals, Ann Neurol, 1998, 44:935-941, 1998, IF: 9.977, CI: 232
7 Hattori N, Yoshino H, Tanaka M, Suzuki H, Mizuno Y. Genotype in the 24-kDa subunit gene (NDUFV2) of mitochondrial complex I and susceptibility to Parkinson disease. Genomics. 1998 Apr 1;49(1):52-8. PubMed PMID: 9570948.
8 Wang M, Hattori N, Shimizu N, Mizuno Y, et al; Polymorphism in the parkin gene in sporadic Parkinson's disease, Ann Neurol, 1999, 45:655-658, IF: 9.977, CI: 81
9 Shimura H, Hattori N, Kubo S, Mizuno Y, et al; Immunohistochemical and subcellular localization of parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients, Ann Neurol, 1999, 45:668-672, IF: 9.977, CI: 210
10 Ide T, Tsutsui H, Kinugawa S, Utsumi H, Hattori N, et al; Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium, Circ Res, 1999, 85:357-363, IF: 11.019, CI: 506
11 Shimizu N, Hattori N, Shintani A, Kawasaki K, Kitada T, Minoshima S, Mizuno Y, Asakawa S. Sequencing analysis of deletion mutations in the giant Parkin gene. Am J Hum Genet, 1999, 65:4, A420, IF: 11.202
12 Nisipeanu P, Inzelberg R, Hattori N, Mizuno Y, et al; Autosomal-recessive juvenile parkinsonism in a Jewish Yemenite kindred: Mutation of Parkin gene, Neurology, 1999, 53:1602-1604, IF: 8.286
13 Shimura-Miura H, Hattori N, Kang DC, Miyako K, Nakabeppu Y, Mizuno Y. Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease, Ann Neurol, 1999, 46:920-924, IF: 9.977, CI: 101
14 Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T. Familial Parkinson disease gene product parkin is a ubiquitin-protein ligase, Nat Genet, 2000, 25:302-305, IF: 29.352, CI: 1450
15 Asakawa S, Hattori N, Mizuno Y, Shimizu N, et al; Molecular analysis of the deletion breakpoints of Parkin gene. Am J Hum Genet, 2000, 67:398-398, IF: 11.202
16 Lu CS, Wu JC, Hattori N, Yoshino H, Mizuno Y, et al; Clinical and genetic studies on familial parkinsonism: The first report on a parkin gene mutation in a Taiwanese family, ‎Mov Disord, 2001, 16:164-166, IF: 5.68
17 Jeon BS, Kim JM, Lee DS, Hattori N, Mizuno Y. An apparently sporadic case with parkin gene mutation in a Korean woman, Arch Neurol, 2001, 58:988-989, IF: 7.419
18 Nisipeanu P, Inzelberg, R, Hattori N, Mizuno Y, et al; Parkin gene causing benign autosomal recessive juvenile parkinsonism, Neurology, 2001, 56:1573-1575, IF: 8.286
19 Imai Y, Soda M, Hattori N, Takahashi R, et al; An unfolded putative transmembrane polypeptide which can lead to endoplasmic reticulum stress is a substrate of parkin, Cell, 2001, 105:891-902, IF: 32.242, CI: 801
20 Shimura H, Schlossmacher MC, Hattori N, Frosch MP, Selkoe DJ, et al; Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease, SCIENCE, 2001, 293:263-269, IF: 33.611, CI: 801
21 Momose Y, Murata M, Hattori N, Toda T, et al; Association studies of multiple candidate genes for Parkinson's disease by using single nucleotide polymorphisms. Am J Hum Genet, 2001, 69:499-499, IF: 11.202
22 Kobayashi H, Kruger R, Hattori N, et al; Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease, BRAIN, 2003, 126:32-42, IF:9.196
23 Sakata E, Hattori N, Kato K. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain, EMBO REPORTS, 2003, 4:301-306, IF: 9.055, CI: 177
24 Rawal N, Periquet M, Hattori N, Brice A, et al;. New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism, French Parkinsons's Dis Genetics S; European Consortium Genetic Sus, Neurology, 2003, 60:1378-1381, IF:8.286, CI: 32
25 Inzelberg, R, Hattori N, Mizuno Y, et al; Camptocormia axial dystonia and parkinsonism: Phenotypic heterogeneity of a parkin mutation, Neurology, 2003, 60:1393-1394, IF: 8.286
26 Hirota Y, Momose Y, Hattori N, Inoko H, Toda T. Genome-wide microsatellite association studies for Parkinson's disease by using the pooled DNA method. Am J Hum Genet, 2003, 73:469, Annual Meeting of the American-Society-of-Human-Genetics, NOV 04-08, 2003, IF: 11.202
27 Maraganore DM, Lesnick, TG, Hattori N, Rocca WA, et al; UCHL1 is a Parkinson's disease susceptibility gene UCHL1 Global Genetics Consortium, Ann Neurol, 2004, 55:512-521, IF: 9.977, CI: 159
28 Hatano Y, Li Y, Hattori N, et al; Novel PINK1 mutations in early-onset parkinsonism, Ann Neurol, 2004, 56:424-427, IF: 9.977, CI: 174
29 Tanaka M, Cabrera VM, Hattori N, Shimodaira H, et al; Mitochondrial genome variation in Eastern Asia and the peopling of Japan, Genome Res, 2004, 14:10A;1832-1850,IF: 14.63,CI: 300
30 Hatano Y, Sato K, Hattori N, et al; PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations, Neurology, 2004, 63:1482-1485, IF: 8.286, CI: 41
31 Moore DJ, Zhang L, Hattori N, Dawson VL, et al;.Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress, Hum Mol Gen, 2005, 14:71-84, IF: 6.393, CI: 164
32 Fukae J, Takanashi M, Hattori N, et al; Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson's disease and related neurodegenerative disorders, Acta Neuropathol, 2005, 109:256-262, IF: 10.762, CI: 54
33 Sato S, Mizuno Y, Hattori N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease, Neurology, 2005, 64:1081-1083, IF: 8.286, CI: 60
34 Li Y, Tomiyama H, Hattori N, et al; Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism, Neurology, 2005, 64:1955-1957, IF: 8.286, CI: 92
35 Orimo S, Amino T, Hattori N, Mizuno Y, et al; Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2, Mov Disord, 2005, 20:1350-1353,IF: 5.68, CI: 41
36 Sato S, Chiba T, Sakata E, Kato K, Mizuno Y, Hattori N, Tanaka K. 14-3-3 eta is a novel regulator of parkin ubiquitin ligase, EMBO JOURNAL, 2006, 25:211-221, IF: 10.434, CI: 67
37 Nishioka K, Hayashi S, Hattori N, et al; Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease, Ann Neurol, 2006, 59:298-309, IF: 9.977, CI: 160
38 Mizuta I, Satake W, Hattori N, Toda T, et al; Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease, Hum Mol Gen, 2006, 15:1151-1158, IF: 6.393, CI: 129
39 Akagawa M, Ito S, Hattori N, Matsuda T, Uchida K, et al; Bispecific Abs against modified protein and DNA with oxidized lipids, PNAS, 2006, 103:6160-6165, IF: 9.674
40 Arai T, Fukae J, Hattori N, et al; Up-regulation of hMUTYH, a DNA repair enzyme in the mitochondria of substantia nigra in Parkinson's disease, Acta Neuropathol, 2006, 112:139-145, IF: 10.762
41 Tomiyama H, Li Y, Hattori N, et al; Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries, Mov Disord, 2006, 21:1102-1108, IF: 5.68, CI: 64
42 Maraganore DM, de Andrade M, Hattori N, et al., Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA, 2006, 296:661-70, IF: 45.54, CI: 393
43 Sato K, Hatano T, Hattori N, Mizuno Y, et al; Prognosis of Parkinson's disease: Time to stage IIi IV, V, and to motor fluctuations, Juntendo Parkinson Study Grp, Mov Disord, 2006, 21:1384-1395, IF: 5.68
44 Ihara M, Yamasaki N, Hattori N, Kinoshita M, et al; Sept4, a component of presynaptic scaffold and Lewy bodies is required for the suppression of alpha-synuclein neurotoxicity. NEURON, 2007, 53:519-533, IF: 15.054, CI: 95
45 Hatano T, Kubo S, Hattori N, et al; Leucine-rich repeat kinase 2 associates with lipid rafts, Hum Mol Gen, 2007, 16:678-690,IF: 6.393, CI: 107
46 Saiki S, Sakai K, Hattori N, Hirose G, et al; Primary skeletal muscle involvement in chorea-acanthocytosis, Mov Disord, 2007, 22:848-852, IF: 5.68
47 Saiki M, Saiki S, Hattori N, Hirose G, et al; Neurological deficits are associated with increased brain calcinosis hypoperfusion and hypometabolism in idiopathic basal ganglia calcification, ‎Mov Disord, 2007, 22:1027-1030, IF: 5.68
48 Obi T, Nishioka K, Hattori N, et al; Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia, Neurology, 2008, 70:238-241, IF: 8.286
49 Ning YP, Kanai K., Hattori N, et al; PARK9-linked parkinsonism in eastern Asia: Mutation detection in ATP13A2 and clinical phenotype, Neurology, 2008, 70:1491-1493, IF: 8.286, CI: 60
50 Ross OA, Braithwaite AT, Hattori N, Farrer MJ, et al; Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. 2008, 63:743-50, IF: 9.977, CI:122
51 Kumazawa R, Tomiyama H, Li Y, Hattori N, et al; Mutation analysis of the PINK1 gene in 391 patients with Parkinson disease, Arch Neurol, 2008, 65:802-808, IF: 7.419
52 Mizuno Y, Hattori N, Kubo S, Mochizuki H, et al; Progress in the pathogenesis and genetics of Parkinson's disease, Philos Trans R Soc Lond B Biol Sci, 2008, 363:2215-2227, IF: 7.055, CI: 50
53 Ross OA, Wu YR, Lee MC, Hattori N, Tan EK, Wu RM, et al; Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol. 2008, 64:88-92, IF: 9.977, CI:102
54 Kanai K, Asahina M, Hattori N, Hattori T, et al; Preserved Cardiac I-123-MIBG Uptake and Lack of Severe Autonomic Dysfunction in a PARK9 Patient. ‎Mov Disord, 2009, 24:1403-1405, IF: 5.68
55 Nishioka K, Ross OA., Farrer MJ, Hattori N, et al; Expanding the Clinical Phenotype of SNCA Duplication Carriers, Mov Disord, 2009, 24:1811-1819, IF:5.68, CI: 51
56 Satake W, Nakabayashi Y, Hattori N, Toda T, et al; Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009, 41:1303-7, IF: 29.352,CI: 844
57 Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA., Sou Y-S, Saiki S, Kawajiri S, Sato F, Kimura M, Komatsu M, Hattori N, Tanaka K. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy, JOURNAL OF CELL BIOLOGY, 2010, 189:211-221, IF: 9.786, CI: 935
58 Mitsui J, Takahashi Y, Hattori N, Tsuji S, et al; Mechanisms of Genomic Instabilities Underlying Two Common Fragile-Site-Associated Loci PARK2 and DMD, in Germ Cell and Cancer Cell Lines, Am J Hum Genet, 2010, 87:75-89, IF: 11.202
59 Yoshino H, Tomiyama H, Hattori N, et al; Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism, Neurology, 2010, 75:1356-1361, IF: 8.286
60 Funayama M, Tomiyama H, Hattori N, et al; Rapid Screening of ATP13A2 Variant with High-Resolution Melting Analysis, ‎Mov Disord, 2010, 25:2434-37, IF: 5.68
61 Saiki S, Sasazawa Y, Hattori N, et al; Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition, Autophagy, 2011, 7:176-187, IF: 11.753, CI: 98
62 Ogaki K, Motoi Y, Li Y, Hattori N, et al; Visual Grasping in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 (Microtubule-Associated with Protein Tau): A Comparison of N-Isopropyl-p-[I-123]-iodoamphetamine Brain Perfusion Single Photon Emission Computed Tomography Analysis with Progressive Supranuclear Palsy. ‎Mov Disord, 2011, 26:561-563, IF:5.68
63 Ross OA, Soto-Ortolaza AI, Hattori N, Farrer MJ, et al; Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 2011, 10:898-908, IF: 21.823, CI: 90
64 Shiba-Fukushima K, Imai Y, Yoshida S, Ishihama Y, Kanao T, Sato S, Hattori N. PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy, Sci Rep, 2012, 2:1002, IF:5.578, CI: 98
65 Liu S, Sawada T, Hattori N, Imai Y, Lu B, et al; Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genet, 2012, 8:e1002537. IF: 7.528, CI:90
66 Funayama M, Yoshino H, Li Y, Kusaka H, Tomiyama H, Hattori N. Pseudo-heterozygous rearrangement mutation of parkin, ‎Mov Disord, 2012, 27:552-555, IF: 5.681
67 Sharma M, Ioannidis JP, Hattori N, Krüger R, et al; GEO-PD Consortium. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology. 2012, 79:659-67, IF: 8.286, CI:54
68 Okatsu, K, Oka T, Hattori N, Mihara K, Tanaka K, Matsuda N, et al; PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria, Nat Commun. 2012, 3:1016, IF: 11.47, CI: 84
69 Ando M, Funayama M, Li Y, Hattori N, et al; VPS35 mutation in Japanese patients with typical Parkinson's disease, ‎Mov Disord, 2012, 27:1413-1417, IF:5.68
70 Hattori N., Hasegawa K., Sakamoto T. Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson's disease, J Clin Pharm Ther, 2012, 37:571-577, IF: 7.903
71 Sharma M, Ioannidis JP, Hattori N, Krüger R, et al; GEOPD consortium. A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J Med Genet. 2012, 49:721-6. IF: 6.335
72 Itokawa K, Sekine T, Hattori N, Araki N, et al; A case of alpha-synuclein gene duplication presenting with head-shaking movements, ‎Mov Disord, 2013, 28:384-387, IF: 5.68
73 Yoritaka A, Takanashi M, Hirayama M, Nakahara T, Ohta S. Hattori N. Pilot study of H-2 therapy in Parkinson's disease: A randomized double-blind placebo-controlled trial, Mov Disord, 2013, 28:836-839, IF:5.68
74 Mizuno Y, Nomoto M, Hattori N, et al; Transdermal Rotigotine in Early Stage Parkinson's Disease: A Randomized, Double-blind, Placebo-controlled Trial, Rotigotine Trial Grp, Mov Disord, 2013, 28:1447-1450, IF:5.68
75 Heckman MG, Soto-Ortolaza AI, Hattori N, Ross OA, et al; Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease, Mov Disord. 2013, 28:1740-4. IF:5.68
76 Yamanaka T. Tosaki A, Hattori N, Nukina N, et al; NF-Y inactivation causes atypical neurodegeneration characterized by ubiquitin and p62 accumulation and endoplasmic reticulum disorganization, Nat. Commun, 2014, 5:3354, IF: 11.47
77 Miyazaki H, Oyama F, Hattori N, Nukina N, et al; Singular localization of sodium channel beta 4 subunit in unmyelinated fibres and its role in the striatum, Nat Commun. 2014, 5:5525, IF: 11.47
78 Hattori N. Cerebral organoids model human brain development and microcephaly, Mov Disord, 2014, 29:185-185, IF: 5.68
79 Furuya N, Ikeda SI, Sato S, Hattori N, Ueno T, et al; PARK2/Parkin-mediated mitochondrial clearance contributes to proteasome activation during slow-twitch muscle atrophy via NFE2L1 nuclear translocation, Autophagy, 2014, 10:631-641, IF: 11.753
80 Okuzumi A, Hatano T, Nakahara T, Yokoyama K, Hattori N. Ophthalmic nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy, Neurology, 2014, 82:1566-1567, IF: 8.286
81 Hattori N. REST as a New Therapeutic Target for Neurodegenerative Disorders, Mov Disord, 2014, 29:869-869, IF: 5.68
82 Shiba-Fukushima K, Inoshita T, Hattori N, Imai Y. PINK1-Mediated Phosphorylation of Parkin Boosts Parkin Activity in Drosophila, PLoS Genet, 2014, 10:e1004391, IF: 7.528,
83 Maraschi A, Ciammola A, Sato S, Hattori N, Sassone J, et al; Parkin regulates kainate receptors by interacting with the GluK2 subunit. Nat Commun, 2014, 5:5182. IF: 11.47
84 Shiba-Fukushima K, Arano T, Hattori N, Imai Y, et al; Phosphorylation of Mitochondrial Polyubiquitin by PINK1 Promotes Parkin Mitochondrial Tethering, PLoS Genet, 2014,10:e1004861, IF:7.528
85 Kurosawa M, Matsumoto G, Hattori N, Nukina N, et al; Depletion of p62 reduces nuclear inclusions and paradoxically ameliorates disease phenotypes in Huntington's model mice, Hum Mol Gen, 2015, 24:1092-1105, IF:6.393
86 Funayama M, Ohe K, Amo T, Furuya N, Yamaguchi J, Saiki S, Li Y, Ogaki K, Ando M, Yoshino H, Tomiyama H, Nishioka K, Hasegawa K, Saiki H, Satake W, Mogushi K, Sasaki R, Kokubo Y, Kuzuhara S, Toda T, Mizuno Y, Uchiyama Y, Ohno K, Hattori N. CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study, Lancet Neurol, 2015, 14:274-282, IF: 30.039, CI: 131
87 Matsuo H, Tomiyama H, Hattori N, Shinomiya N, et al; ABCG2 variant has opposing effects on onset ages of Parkinson's disease and gout, Ann Clin Transl Neurol, 2015, 2:302-306, IF:6.34
88 Mitsui J, Matsukawa T, Hattori N, Tsuji S, et al; Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol. 2015, 2:417-26. IF: 6.34
89 Funayama M, Hattori N. CHCHD2 and Parkinson's disease Reply, Lancet Neurol, 2015, 14:682-683, IF:21.823
90 Matsumoto G, Shimogori T, Hattori N, Nukina N. TBK1 controls autophagosomal engulfment of polyubiquitinated mitochondria through p62/SQSTM1 phosphorylation, Hum Mol Gen, 2015, 24:4429-4442, IF:6.393,
91 Imai Y, Kobayashi Y, Nukina N. Hattori N, Takahashi R, et al; The Parkinson's Disease-Associated Protein Kinase LRRK2 Modulates Notch Signaling through the Endosomal Pathway, PLoS Genet, 2015,11:e1005503, IF:7.528
92 Wang L, Aasly JO, Hattori N, Sharma M, et al; GEO-PD Consortium. Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. Neurology, 2015, 85:1283-1292, IF:8.286
93 Ogaki K, Koga S, Hattori N, Ross OA, et al; Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders, Neurology, 2015, 85:2016-25,IF:8.286
94 Hatano T, Kurita N, Kobayashi M, Hattori N. Teaching Video NeuroImages: Re-emergent jaw tremor in Parkinson disease. Neurology, 2015, 85:e181,IF:8.286
95 Hatano T, Saiki S, Okuzumi A, Mohney RP, Hattori N. Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. Journal of neurology, neurosurgery, and psychiatry, 2016, 87:295-301, IF: 7.349
96 Takanashi M, Li Y, Hattori N. Absence of Lewy pathology associated with PINK1 homozygous mutation, Neurology, 2016, 86:2212-2213, IF: 7.592
97 Kamagata K, Hatano T, Okuzumi A, Motoi Y, Abe O, Shimoji K, Kamiya K, Suzuki M, Hori M, Kumamaru K, Hattori N, Aoki S. Neurite orientation dispersion and density imaging in the substantia nigra in idiopathic Parkinson disease, Euro Radiol, 2016, 26:2567-2577, IF: 5.117
98 Sato S, Koike M, Funayama M, Ezaki J, Fukuda T, Ueno T, Uchiyama Y, Hattori N. Lysosomal Storage of Subunit c of Mitochondrial ATP Synthase in Brain-Specific Atp13a2-Deficient Mice, Am J Pathol, 2016, 186:3074-3082, IF; 4.057
99 Matsushima T, Conedera S, Tanaka R, Li Y, Yoshino H, Funayama M, Ikeda A, Hosaka Y, Okuzumi A, Shimada Y, Yamashiro K, Motoi Y, Nishioka K, Hattori N. Genotype-phenotype correlations of cysteine replacement in CADASIL, Neurobiol. Aging, 2017, 50:169.e7, IF: 5.117
100 Meng H, Yamashita C, Shiba-Fukushima K, Inoshita T, Funayama M, Sato S, Hatta T, Natsume T, Umitsu M, Takagi J, Imai Y, Hattori N. Loss of Parkinson's disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c, Nat Commun, 2017,
101 Inoshita T, Arano T, Hosaka Y, Meng H, Umezaki Y, Kosugi S, Morimoto T, Koike M, Chang H-Y, Imai Y, Hattori N. Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in Drosophila, Hum Mol Genet, 2017, 26:2933-2948, IF: 5.34
102 Shiba-Fukushima K, Ishikawa KI, Inoshita T, Izawa N, Takanashi M, Sato S, Onodera O, Akamatsu W, Okano H, Imai Y, Hattori N. Evidence that phosphorylated ubiquitin signaling is involved in the etiology of Parkinson's disease. Hum Mol Genet. 2017, 26(16):3172-3185. IF: 5.34
103 Saiki S, Hatano T, Fujimaki M, Ishikawa KI, Mori A, Oji Y, Okuzumi A, Fukuhara T, Koinuma T, Imamichi Y, Nagumo M, Furuya N, Nojiri S, Amo T, Yamashiro K, Hattori N. Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson's disease. Sci Rep. 2017 Aug 4;7(1):7328. IF:4.259
104 Hattori N, Arano T, Hatano T, Mori A, Imai Y. Mitochondrial-Associated Membranes in Parkinson's Disease. Adv Exp Med Biol. 2017;997:157-169.
105 Hattori N, Mizuno Y. Twenty years since the discovery of the parkin gene. J Neural Transm (Vienna). 2017 Sep;124(9):1037-1054
106 Ren Q, Ma M, Yang J, Nonaka R, Yamaguchi A, Ishikawa KI, Kobayashi K, Murayama S, Hwang SH, Saiki S, Akamatsu W, Hattori N, Hammock BD, Hashimoto K. Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5815-E5823. IF: 9.58
107 Taniguchi D, Hatano T, Kamagata K, Okuzumi A, Oji Y, Mori A, Hori M, Aoki S, Hattori N. Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease. Mov Disord. 2018 Sep;33(9):1488-1492. IF: 8.679
108 Yoritaka A, Ohtsuka C, Maeda T, Hirayama M, Abe T, Watanabe H, Saiki H, Oyama G, Fukae J, Shimo Y, Hatano T, Kawajiri S, Okuma Y, Machida Y, Miwa H, Suzuki C, Kazama A, Tomiyama M, Kihara T, Hirasawa M, Shimura H, Oda E, Ito M, Ohno K, Hattori N. Randomized, double-blind, multicenter trial of hydrogen water for Parkinson's disease. Mov Disord. 2018 Sep;33(9):1505-1507. IF: 8.679
109 Fujimaki M, Saiki S, Li Y, Kaga N, Taka H, Hatano T, Ishikawa KI, Oji Y, Mori A, Okuzumi A, Koinuma T, Ueno SI, Imamichi Y, Ueno T, Miura Y, Funayama M, Hattori N. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology. 2018 Jan 30;90(5):e404-e411. IF: 8.055
110 Mishima T, Fujioka S, Tomiyama H, Yabe I, Kurisaki R, Fujii N, Neshige R, Ross OA, Farrer MJ, Dickson DW, Wszolek ZK, Hattori N, Tsuboi Y. Establishing diagnostic criteria for Perry syndrome. J Neurol Neurosurg Psychiatry. 2018 May;89(5):482-487. IF: 8.272
111 Okuzumi A, Kurosawa M, Hatano T, Takanashi M, Nojiri S, Fukuhara T, Yamanaka T, Miyazaki H, Yoshinaga S, Furukawa Y, Shimogori T, Hattori N, Nukina N. Rapid dissemination of alpha-synuclein seeds through neural circuits in an in-vivo prion-like seeding experiment. Acta Neuropathol Commun. 2018 Sep 19;6(1):96. IF: 6.27
112 Takanashi M, Funayama M, Matsuura E, Yoshino H, Li Y, Tsuyama S, Takashima H, Nishioka K, Hattori N. Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations. Acta Neuropathol Commun. 2018 Oct 17;6(1):105. IF: 6.27
113 Sato S, Uchihara T, Fukuda T, Noda S, Kondo H, Saiki S, Komatsu M, Uchiyama Y, Tanaka K, Hattori N. Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice. Sci Rep. 2018 Feb 12;8(1):2813.
114 Ueno SI, Saiki S, Fujimaki M, Takeshige-Amano H, Hatano T, Oyama G, Ishikawa KI, Yamaguchi A, Nojiri S, Akamatsu W, Hattori N. Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease. Cells. 2018 Dec 29;8(1). pii: E14. doi: 10.3390/cells8010014. IF: 36.216
115 Ikeda A, Shimada H, Nishioka K, Takanashi M, Hayashida A, Li Y, Yoshino H, Funayama M, Ueno Y, Hatano T, Sahara N, Suhara T, Higuchi M, Hattori N. Clinical heterogeneity of frontotemporal dementia and Parkinsonism linked to chromosome 17 caused by MAPT N279K mutation in relation to tau positron emission tomography features. Mov Disord. 2019 Apr;34(4):568-574. IF: 8.679
116 Saiki S, Sasazawa Y, Fujimaki M, Kamagata K, Kaga N, Taka H, Li Y, Souma S, Hatano T, Imamichi Y, Furuya N, Mori A, Oji Y, Ueno SI, Nojiri S, Miura Y, Ueno T, Funayama M, Aoki S, Hattori N. A metabolic profile of polyamines in parkinson disease: A promising biomarker. Ann Neurol. 2019 Aug;86(2):251-263, IF: 10.244
117 Mori A, Hatano T, Inoshita T, Shiba-Fukushima K, Koinuma T, Meng H, Kubo SI, Spratt S, Cui C, Yamashita C, Miki Y, Yamamoto K, Hirabayashi T, Murakami M, Takahashi Y, Shindou H, Nonaka T, Hasegawa M, Okuzumi A, Imai Y, Hattori N. Parkinson's disease-associated iPLA2-VIA/PLA2G6 regulates neuronal functions and α-synuclein stability through membrane remodeling. Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20689-20699. IF: 9.58
118 Okuzumi A, Hatano T, Kamagata K, Hori M, Mori A, Oji Y, Taniguchi D, Daida K, Shimo Y, Yanagisawa N, Nojiri S, Aoki S, Hattori N. Neuromelanin or DaT-SPECT: which is the better marker for discriminating advanced Parkinson's disease? Eur J Neurol. 2019 Nov;26(11):1408-1416.
119 Imai Y, Inoshita T, Meng H, Shiba-Fukushima K, Hara KY, Sawamura N, Hattori N. Light-driven activation of mitochondrial proton-motive force improves motor behaviors in a Drosophila model of Parkinson's disease. Commun Biol. 2019 Nov 22;2:424, IF: 11.880
120 Ikeda A, Nishioka K, Meng H, Takanashi M, Hasegawa I, Inoshita T, Shiba-Fukushima K, Li Y, Yoshino H, Mori A, Okuzumi A, Yamaguchi A, Nonaka R, Izawa N, Ishikawa KI, Saiki H, Morita M, Hasegawa M, Hasegawa K, Elahi M, Funayama M, Okano H, Akamatsu W, Imai Y, Hattori N. Mutations in CHCHD2 cause α-synuclein aggregation. Hum Mol Genet. 2019 Dec 1;28(23):3895-3911. IF: 5.1
121 Ogawa T, Hatano T, Oyama G, Takanashi M, Taniguchi D, Hattori N. Graphic Summary of Movement Disorders Society Criteria for Progressive Supranuclear Palsy and Multiple Allocations eXtinction Rules. Mov Disord Clin Pract. 2020 Jan 20;7(2):240-242.
122 Miyamoto N, Magami S, Inaba T, Ueno Y, Hira K, Kijima C, Nakajima S, Yamashiro K, Urabe T, Hattori N. The effects of A1/A2 astrocytes on oligodendrocyte linage cells against white matter injury under prolonged cerebral hypoperfusion. Glia. 2020 Feb 28. doi: 10.1002/glia.23814. Epub ahead of print. IF:5.984, CI:3
123 Oji Y, Hatano T, Ueno SI, Funayama M, Ishikawa KI, Okuzumi A, Noda S, Sato S, Satake W, Toda T, Li Y, Hino-Takai T, Kakuta S, Tsunemi T, Yoshino H, Nishioka K, Hattori T, Mizutani Y, Mutoh T, Yokochi F, Ichinose Y, Koh K, Shindo K, Takiyama Y, Hamaguchi T, Yamada M, Farrer MJ, Uchiyama Y, Akamatsu W, Wu YR, Matsuda J, Hattori N. Variants in saposin D domain of prosaposin gene linked to Parkinson's disease. Brain. 2020 Mar 23:awaa064. doi: 10.1093/brain/awaa064, IF: 11.814, CI:8
124 Hattori N, Mochizuki H, Hasegawa K, Nomoto M, Uchida E, Terahara T, Okawa K, Fukuta H. Ropinirole Patch Versus Placebo, Ropinirole Extended-Release Tablet in Advanced Parkinson's Disease. Mov Disord. 2020 Sep;35(9):1565-1573. doi: 10.1002/mds.28071. IF: 8.679, CI:2
125 Li Y, Ikeda A, Yoshino H, Oyama G, Kitani M, Daida K, Hayashida A, Ogaki K, Yoshida K, Kimura T, Nakayama Y, Ito H, Sugeno N, Aoki M, Miyajima H, Kimura K, Ueda N, Watanabe M, Urabe T, Takanashi M, Funayama M, Nishioka K, Hattori N. Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan. J Hum Genet. 2020 Sep;65(9):771-781. doi: 10.1038/s10038-020-0772-4. IF: 2.942,
126 Takeshige-Amano H, Saiki S, Fujimaki M, Ueno SI, Li Y, Hatano T, Ishikawa KI, Oji Y, Mori A, Okuzumi A, Tsunemi T, Daida K, Ishiguro Y, Imamichi Y, Nanmo H, Nojiri S, Funayama M, Hattori N. Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. Mov Disord. 2020 Aug;35(8):1438-1447. doi: 10.1002/mds.28068. IF: 8.679, CI:2
127 Hattori N, Kitabayashi H, Kanda T, Nomura T, Toyama K, Mori A. A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease. Mov Disord. 2020 Aug;35(8):1481-1487, doi: 10.1002/mds.28095. IF: 8.679
128 Daida K, Nishioka K, Li Y, Yoshino H, Shimada T, Dougu N, Nakatsuji Y, Ohara S, Hashimoto T, Okiyama R, Yokochi F, Suzuki C, Tomiyama M, Kimura K, Ueda N, Tanaka F, Yamada H, Fujioka S, Tsuboi Y, Uozumi T, Takei T, Matsuzaki S, Shibasaki M, Kashihara K, Kurisaki R, Yamashita T, Fujita N, Hirata Y, Ii Y, Wada C, Eura N, Sugie K, Higuchi Y, Kojima F, Imai H, Noda K, Shimo Y, Funayama M, Hattori N. PLA2G6 variants associated with the number of affected alleles in Parkinson's disease in Japan. Neurobiol Aging. 2021 Jan;97:147.e1-147.e9. IF:4.347 doi:10.1016/j.neurobiolaging.2020.07.004. Epub 2020 Jul 13. PMID: 32771225.
129 Tokarew JM, El-Kodsi DN, Lengacher NA, Fehr TK, Nguyen AP, Shutinoski B, O'Nuallain B, Jin M, Khan JM, Ng ACH, Li J, Jiang Q, Zhang M, Wang L, Sengupta R, Barber KR, Tran A, Im DS, Callaghan S, Park DS, Zandee S, Dong X, Scherzer CR, Prat A, Tsai EC, Takanashi M, Hattori N, Chan JA, Zecca L, West AB, Holmgren A, Puente L, Shaw GS, Toth G, Woulfe JM, Taylor P, Tomlinson JJ, Schlossmacher MG. Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites. Acta Neuropathol. 2021 Mar 10. doi: 10.1007/s00401-021-02285-4. Epub ahead of print. IF:14.256

研究者 教育活動 ホームページURL